Short answer
MeiraGTx Holdings plc (MGTX) filed an 8-K current report with the SEC on April 16, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Three-year AQUAx data for AAV-hAQP1 in grade 2/3 radiation-induced xerostomia.
MeiraGTx Holdings plc 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Three-year AQUAx data for AAV-hAQP1 in grade 2/3 radiation-induced xerostomia
- Phase 1 durability update supports longer-term assessment of treatment benefit
- Press release dated April 16, 2026 contains the substantive clinical findings
Item 8.01 · Other Events
- Phase 1 AQUAx data showed AAV-hAQP1 safety through 3 years, with no dose-limiting toxicity or treatment-related serious adverse events
- XQ improvement reached 62% of participants at 36 months, with the 17-point average improvement sustained
- Saliva flow normalized to 0.34 mL/min at 36 months versus 0.36 mL/min at 12 months
- Management estimates peak global annual revenue potential of approximately $3.7B, including approximately $2.0B in the U.S.
- Commercial projections remain contingent on later-stage validation, regulatory approval, manufacturing execution and financing needs
Item EX-99.1 · Exhibit EX-99.1
- Three-year Phase 1 AQUAx data show sustained xerostomia symptom improvements in bilateral and unilateral cohorts
- Unstimulated whole saliva flow increases maintained through 3 years, supporting durable biological activity
- AAV-hAQP1 safe and well tolerated across each tested dose
- One-time treatment durability strengthens potential disease-modifying and commercial positioning
- Phase 1 remains open-label and non-randomized, leaving regulatory efficacy and approval risk unresolved
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MeiraGTx Holdings plc 8-K filings
Get the next MGTX 8-K as it lands
Follow MGTX for push alerts, or ask the research agent what this filing means.